UBS 21ST ANNUAL GLOBAL HEALTHCARE

UBS 21ST ANNUAL GLOBAL HEALTHCARE
SERVICES CONFERENCE
February 7 , 2011
1
DROGASIL : Brief Profile
1935- Drogasil is
founded on March 28, 1935, when
owners of two small pharmacy chains, Drogaria Bráulio and
Drogaria Brasil, combined their respective experience and
financial resources to form a new company under the name
Drogasil Ltda.
1972- Drogasil became a corporation (sociedade anônima).
1977- Drogasil
became registered as a public company
with the CVM(Brazilian SEC).
1979- Drogasil is pioneer on developing self service concept
Drogasil HQ (1941) - Rua José Bonifácio, 166 - SP
on pharma retail sales.
2000- Drogasil speeds the information technology systems
process to create a network linkage for all its stores with
distribution center. In a turnaround process, implemented
several other measures to increase the efficiency on
inventory control, cash and sales activity reports.
2007- Drogasil register for the "Novo Mercado" listing
segment, highest level of corporate governance at
BM&Fbovespa. IPO on July 3rd, 2007. As of Jan 2011,
Drogasil is listed on the following BM&Fbovespa indices:
ICON; IGCT; ITAG; IGC.
SP- Gabriel
Monteiro Silva
DROGASIL : Brief Profile
Fone Farmácia
Home Delivery.
Call Center
Drogasil CRM.
Affiliate cards
Dermocenter
Skin Care Sales with
Pharmacist Consultancy.
Programa Farmácia Popular do
Brasil- Co Payment Program
Developed by Brazilian Health
Ministry offer discounts on
selected drugs from therapeutic
classes related to birh control,
blood pressure, diabetes ,
asthma and obesity
Beauty Center
Beauty and Make Up center with Sales
Assitance from beauty specialists.
Pharmacists Consultancy
Pharmacists in place during
Drugstore working hours.
As of Dec , 2010
1,116 Pharmacists for 338 Stores.
DROGASIL in BRAZIL
base: Jan 12, 2011
342 Drugstores
in
BRASIL
Distribution
Center
Minas Gerais
STORES 28
BRASILIA (DF)
STORES 52
GOIAS
STORES 32
Rio de Janeiro
STORES 6
Legenda
SÃO PAULO)
Espírito Santo
STORES 210
STORES 14
(1/2)
4
DROGASIL in BRAZIL


















Base: Dec, 2010
338 stores
6 Brazilian states
88 Brazilian cities.
13 stores in Supermarkets/hypermarkets.
40 stores located in shopping malls.
34 stores open 24 hours.
284 street stores.
1 Delivery.
1,116 pharmacists.
6,552 employees in store operation.
Total : 7,561 employees
Sales area: 44,779 sq. m².
Average sales area: 136 sq. m²
Average employee per store: 20 employees
2 Distribution centers: S.Paulo e Contagem
Second Largest Drugstore chain in Brazil
(Abrafarma revenue criteria)
Brand Analytics ranks Drogasil brand in 39th among top 50
Brazilian brands.
Brazil Drug market share of 4.3%.
(IMS Health match sept,2010)
(2/2)
5
DROGASIL : THE EXPANSION
338
283
In 4 years:
159 New Stores.
DROGASIL: Drugstore
chain expansion CAGR
17,2% pa
256
211
179
164
151
42
48
55
2004
2005
2006
62
67
78
88
2007
2008
2009
2010
Cities
Qty Stores
1/4
6
DROGASIL : THE EXPANSION
2007- 10 Store location acquisition in
Goiânia City.
2007- New stores: 32 stores . Net
addition: 32 stores.
2008- Drugstore chain acquisition with
24 stores in Brasília(DF).
2008- New Stores: 46. Net Addition: 45
stores.
SP- São Carlos
2009- 12 store location acquisition in
57
60
50
55
Espírito Santo.
46 45
2009- New Stores: 28. Net Addition: 27
40
stores.
32 32
28 27
30
2010- 19 store location acquisition in
20
Brasilia(DF) plus 4 stores in Goias
10
2010- New stores: 57. Net Addition: 55
0
2007
2008
New Stores
2009
Net Addition
2010
(2/4)
stores.
7
DROGASIL : THE
EXPANSION
SALES AREA & STORES- Evolution.
45.000
350
40.000
300
Adition of 12,204 sq.m²
sales area
35.000
250
30.000
200
25.000
41.945
20.000
150
29.741
15.000
20.772
100
10.000
50
5.000
151
211
315
0
0
2004
2007
set-10
QTY STORES
Rio de Janeiro- Niteroi- Icaraí
(3/4)
Espírito Santo- Praia do Canto
8
DROGASIL : THE EXPANSION
16.000
Employee Staff- Evolution
671
14.000
322
Adition of 2,936
employees
12.000
6.191
10.000
8.000
314
220
6.000
3.714
206
191
4.000
2.216
7.184
4.248
2.000
2.613
0
2004
2007
Total Staff
DF- Ceilândia
(4/4)
Stores
Adm.
set-10
Distribution
9
DRUG RETAIL IN BRASIL - SALES in R$(000)
35.000
25,0%
C.A.G.R : 11.,9% A.A .
30.000
20,2%
20,0%
25.000
16,0%
15,0%
14,5%
20.000
11,9%
11,5%
15.000
9,9%
10,0%
0
R$ 32.937
R$ 27.412
R$ 30.231
R$ 26.397
R$ 23.583
R$ 21.452
5.000
R$ 19.231
10.000
5,0%
0,0%
Fonte: IMS Health New Flash Novembro2010
Valor R$
OYA R$
10
DRUG RETAIL in BRASIL - Units, Sales in U$D(000)
20000
45,0%
$18.685
42%
18000
$12.179
24%
$9.868
10000
15,0%
5,6%
5%
10,0%
1.883
1.517
1.436
5,3%
8,3%
7,6%
4,5%
1.374
2000
17,2%
1.606
4000
25,0%
20,0%
1.768
6000
30,0%
20%
1.632
$7.955
8000
23%
35%35,0%
$13.830
$14.648
14000
12000
$15.437
16000
40,0%
0
5,0%
0,0%
Source: IMS Health Flash Nov2010
UNIT
Value USD
OYA Growth. UNIT
OYA Growth. USD
11
PHARMA RETAIL MARKET IN BRAZIL
3,0%
0,0%
12
11,4%
11,0%
12,0%
12,6%
8,5%
10,1%
11,7%
11,6%
12,8%
14,6%
12,2%
10,9%
11,2%
12,5%
14,6%
11,9%
13,6%
7,8%
6,0%
11,4%
9,0%
9,6%
12,0%
12,5%
15,3%
15,7%
15,0%
11,9%
18,0%
14,9%
DRUGS, COSMETICS, PERSONAL CARE GROWTH YoY : IBGE- nominal retail sales Brasildessazonalized
( Base avg 2003= 100)
DRUG RETAIL IN BRAZIL
18Bi
15Bi
21Bi
25Bi
30Bi
Drug Retail- Revenue Share in Brazil
100%
Stores
Qty
2%
2%
3%
3%
3%
58%
57%
53%
51%
49%
2,324(4%)
8%
11%
11%
7%
10%
33%
33%
34%
35%
36%
3,091(5%)
March-06
March-07
March-08
March-09
673 (1%)
90%
80%
70%by
Sales
Store
Type
60%
56,256(90%)
50%
40%
30%
20%
10%
0%
March-10 Total: 62,354
Source: IMS
Abrafarma
Other DrugChains
Independent
Supermarkets
13
DRUG RETAIL IN BRAZIL
Top 5 Generic Manufacturers in Brazil
Criteria:
YTD Local Currency
MEDLEY
EMS PHARMA
EUROFARMA
ACHE
GERMED PHARMA
Source: IMS Flash Dec 2010
Top 5 Therapeutic Classes in Brazil
Criteria:
YTD Local Currency
Analgesic Non Narcotic
Hormonas Contraceptive
Anti-Rheumatic
Anti-Depressive
Anti-Ulcer
Source: IMS Flash Dec 2010
dez-10
32,7%
24,3%
6,3%
5,8%
5,7%
dez-10
4,7%
4,2%
3,5%
3,42
3,1%
Top 5 Manufacturers in Brazil
Criteria:
YTD Local Currency
EMS PHARMA
MEDLEY
SANOFI-AVENTIS
ACHE
EUROFARMA
Source: IMS Flash Dec 2010
Top 5 Drug Markets in Brazil
Criteria:
YTD Local Currency
São Paulo
Rio de Janeiro
Minas Gerais
Rio Grande Sul
Parana
Source: IMS Flash Dec 2010
dez-10
7,0%
6,3%
5,4%
5,3%
3,8%
dez-10
30,3%
13,1%
9,6%
7,6%
5,8%
14
DROGASIL: SALES PERFORMANCE
Sales Breakdown
3Q10
DRUGS
GENERIC
OTC DRUGS
14,0%
71,1%
16,2%
BRANDED
69,9%
Non Drugs
0,0%
28,9%
20,0%
40,0%
60,0%
80,0%
9M09
Medicamentos
74%
DRUGS
GENERIC
OTC DRUGS
26%
14,2%
73,3%
17,1%
BRANDED
68,7%
Non Drugs
0,0%
26,7%
20,0%
40,0%
60,0%
80,0%
15
Total
DROGASIL
3Q10
3Q09
9M09
92,0%
2009
2008
41.945
37.175
41.945
37.175
37.963
34.537
Sales Area - M² total avg
40.950
36.951
39.539
35.830
36.247
32.661
Number of Stores - eop
315
278
315
278
283
256
Number of Stores - avg
308
274
299
267
270
238
13.755
12.716
39.468
36.035
48.950
40.626
6.191
5.244
6.191
5.244
5.346
4.571
Number of Store Employees - eop
37,2%
12,9%
9,2%
- 3 Years
Sales Area - M² total eop
Quantity Transactions (000)
17,1%
5,0%
+ 3 Years
9M10
27,9%
8,6%
29,3%
82,5%
27,4%
18,3%
52,0%
15,5%
19,0%
55,9%
15,6%
12,3%
44,4%
16,5%
50%
45%
40%
35%
30%
25%
20%
15%
10%
5%
0%
19,1%
DROGASIL: SALES PERFORMANCE
TICKET
Avg Ticket: 3Q10 = R$39,0
Avg Ticket : 3Q09 = R$37,2
Growth : 4.8%
TRANSACTIONS
Growth: 8.1%
16
DROGASIL: SALES PERFORMANCE
SAME STORE SALES- QUARTER ANALYSIS
15%
10%
26%
25%
21%
20%
20%
9%
11%
25%
20%
30%
27%
29%
28%
24%
22%
21%
17%
15%
14%
13%
16%
20%
18%
20%
20%
19%
Qo…
5%
0%
QoQal
(3/3)
17
DROGASIL: Financial Performance
Gross Sales Revenue
R$ milhões
Gross Margin
34 ,8 %
18 ,2 %
1 .787 ,8
1 .530 ,1
% Gross Profit compared to Gross Sales
24 ,0%
22,6%
23,0%
22,5% 22,2%
22,3500
% ,0
398,8
352,5
400 , 0
22 ,0%
1 .326 ,6
1 .294 ,8
450 , 0
292,8
294,2
20 ,0%
350 , 0
300 , 0
1006
18 ,0%
250 , 0
200 , 0
16 ,0%
226,8
14 ,0%
150 , 0
100 , 0
12 ,0%
50, 0
-
10 ,0%
9 M09 9 M10
2007
2008
2009
9M09 9M10
2007 2008 2009
Margem
(1/10)
18
DROGASIL: Financial Performance
450,0
S.G.A. with Board Fees)
R$ millions
18,3%18,4%
17,2% 20,0%
400,0
350,0
17,2%17,7%
307,3
244,7
184,5
300,0
250,0
200,0
173,5
143,3
150,0
100,0
50,0
-
18,0%
16,0%
14,0%
12,0%
10,0%
8,0%
6,0%
4,0%
2,0%
0,0%
% Gros s Revenue Sales
(2/10)
19
DROGASIL: Financial Performance
NET PROFIT
R$ milhões
EBITDA
45,8%
23 ,7 %
79 ,4 %
R$ milhões
19,8%
90,0
120,0
20,0%
100,0
74,6
80,0
66,9
70,0
60,0
25,0%
55,9
8,0%
88,2
6,8%
51,2
118 ,6
109 ,1
7,0%
7,1%
66 ,1
80,0
51,2
60,0
5,1% 5,0%
6 ,6 %
5,0%
15,0%
50,0
32,8
40,0
10,0%
30,0
4,3%
4,4%
20,0
2,0%
5,0%
20,0
1,0%
10,0
-
0,0%
9M099M10
4,0%
3,0%
40,0
4,2%
3,3% 3,9%
6,0%
-
0,0%
9 M09 9 M10
2007 2008 2009
2007 2008 2009
EBITDA margin gross sales
% GROSS REVENUE SALES
(3/10)
20
DROGASIL: Financial Performance
R$ 90.000
CAPEX INVESTMENTS
values in R$000
Cummulative
investments of
R$222,589
R$ 80.000
 Investments & Cash= R$107,190
R$ 70.000
 Total Debt= R$55,787
R$ 76.755
R$ 63.046
R$ 60.000
R$ 49.854
R$ 50.000
 Short Term Debt= R$21,379
R$ 40.000
R$ 32.934
 Long Term Debt.= R$34,408
R$ 30.000
 Net Worth= R$458,096
R$ 20.000
R$ 10.000
 Net Cash = R$60,255
R$ 0
2007
 On Sept 28, 2010, Drogasil did a Block-Trade of
2008
2009
9M10
3,1mm stocks at BM&Fbovespa. On that date, o
DROG3 share price closed up 1,85% rated at
R$41,25/share . Value credit on Oct 01, 2010.
 (all values expressed in R$000)
(4/10)
21
DROGASIL: Financial Performance
WORKING CAPITAL : Inventory Days
DIAS EM ESTOQUE - TOTAL
UNIDADES (MIL)
CD
Lojas
Total
25
55
27
49
28
29
55
54
59
52
54
50
49
51
50
54
60
54
60
70
40
30
20
27
27
26
24
29
26
27
24
27
22
29
28
32
23
29
30
31
27
28
22
27
24
10
-
22
DROGASIL: Financial Performance
Gross Revenue Sales
Gross Revenue Sales
Net Sales
9M10
1.530.140
1.469.010
9M09
1.294.858
1.246.175
2Q10
536.856
514.690
S/ Vd Bruta
Current Assets
Checks
Debit & Credit Cards
Others
(-) Provision for Bad Debt
Taxes to Recover
Difered Income Tax
Inventories
3Q10
513.348
492.949
S/ Vd Bruta
S/ Vd Bruta
3Q09
2Q09
474.073
456.017
441.377
425.228
S/ Vd Bruta
S/ Vd Bruta
S/ Vd Bruta
3.922
0,3%
3.922
0,7%
4.249
0,8%
5.073
0,4%
5.073
1,1%
5.177
1,2%
97.186
6,4%
97.186
18,1%
94.277
18,4%
83.943
6,5%
83.943
19,0%
79.032
17,9%
7.607
0,5%
7.607
1,4%
7.252
1,4%
6.561
0,5%
6.561
1,5%
6.743
1,5%
(511)
0,0%
(511)
-0,1%
-0,1%
(914)
-0,2%
(906)
-0,2%
55.336
3,6%
55.336
10,3%
51.142
10,0%
40.608
3,1%
40.549
9,2%
34.156
7,7%
5.245
0,3%
5.245
1,0%
5.119
1,0%
5.509
0,4%
5.509
1,2%
5.375
1,2%
257.457
16,8%
257.457
48,0%
244.846
47,7%
230.639
17,8%
230.639
52,3%
217.578
49,3%
Suppliers
Taxes
Salaries
Rentals
Tenure Entitlement
169.567
11,1%
169.567
31,6%
137.466
26,8%
156.525
12,1%
156.525
35,5%
126.308
28,6%
15.907
1,0%
15.907
3,0%
19.195
3,7%
15.792
1,2%
15.792
3,6%
17.040
3,9%
35.332
2,3%
35.332
6,6%
29.377
5,7%
33.926
2,6%
33.926
7,7%
28.384
6,4%
3.805
0,2%
3.805
0,7%
3.396
0,7%
3.055
0,2%
3.055
0,7%
2.983
0,7%
150
0,0%
150
0,0%
158
0,0%
849
0,1%
849
0,2%
549
0,1%
Current Assets
Current Liabilities
426.242
224.760
W.I.>
201.482
32.274
19
(503)
-0,1%
(914)
Current Liabilities
Additional W.C>
Days on Receivables
426.242
224.760
13,2%
2,1%
201.482
(15.306)
18
406.381
189.592
37,5%
-2,9%
371.418
210.146
371.359
210.146
12,5% 161.213
36,5%
(10.678)
18
-2,4%
18
161.272
631
20
216.788
10.999
42,2%
2,1%
0,0%
347.156
175.265
171.891
12.964
18
Inventories
62
59
60
65
59
61
Suppliers
41
39
34
44
40
35
Icms
13
13
12
11
10
9
54
51
57
52
47
53
Cash Cycle
6/10
38,9%
2,9%
23
DROGASIL: Financial Performance
RECEIVABLE METHOD - 2008
Others;
5%
Cash; 33%
Credit Card;36%
Checks; 2%
Receivable Method - 2009
Others; 3,7%
Debit Card; 21%
Pre Dated Checks; 3%
Cash; 32%
Credit Card; 38,4%
Checks; 1,5%
Debit Card; 22%
Pre Dated Checks; 2,4%
7/10
24
DROGASIL: Financial Performance
RECEIVABLE
METHOD - 9M 2010
Others; 3%
Cash; 31%
Credit Card; 40%
55.0%
CASH
Checks; 1%
Debit Card; 23%
Pre- Dated checks; 2%
8/10
25
DROGASIL: Financial Performance
DROG3- EBITDA YoY X EV/EBITDA -LTM
25,0
100%
91%
23,1
91%
90%
76%
20,0
80%
18,0
70%
15,0
15,0
14,6
13,4
11,7
10,0
13,4
46%
11,0
39%
34%
8,0
23%
17%
5,0
7,5
52%
13,1 13,1
11,4
36%
29%
60%
50%
40%
30%
6,9
15%
20%
10%
8%
0,0
10%
0%
2Q07 3Q07 4Q07 1Q08 2Q08 3Q08 4Q08 1Q09 2Q09 3Q09 4Q09 1Q10 2Q10 3Q10
EBITDA Growth
(9/10)
EV/EBITDA
26
DROGASIL: Financial Performance
10,0%
76.755
3,5%
32.274
631
44.835
37.457
19.518
179
5,0%
(15.306)
3,3%
4,6%
(10.678)
150
5,3%
5,1%
18.038
151
164
200
11.419
7,1%
211
6,8%
62.223
6,6%
250
49.392
256
300
278
283
315
350
100
NOPLAT
50
42
48
67
62
55
78
77
CAPEX
Var W.I
82
3Q 09
0
3Q 10
9M09
9M10
0,0%
2004
2005
2006
Cities
2007
Qty Stores
9M9
NOPLAT
2008
49.392
EBITDA
88.235
(-) Depreciation (15.635)
EBIT
72.600
(-) Inc. Tax
(23.208)
NOPLAT
49.392
2009
9M09
9M10
EBITDA Margem% Gross Sales Rev.
9M10
9M9
9M10
49.392
37.457
161.213
631
24,9%
62.223
76.755
201.482
32.274
22,4%
62.223
109.185
(21.538)
87.647
(25.424)
62.223
(10/10)
NOPLAT
CAPEX
W.I.
Var W.I.
ROIC
27
DROGASIL: BENCHMARK
Retail Pharmacy Segment
CVS
Net Sales
Sales Growth
Gross Profit
Gross Margin
S.G.A.
S.G.A
Dec-09
Dec-08
Dec-07
$55.355,0
$48.989,9
$45.086,5
13,0%
8,7%
11,9%
$16.593,0
$14.704,4
$13.110,6
30,0%
30,0%
29,1%
$ 12.434,0 $ 10.988,0 $ 10.151,0
22,5%
22,4%
22,5%
DROGASIL
Net Sales
Sales Growth
Gross Profit
Dec-09
Dec-08
Dec-07
1,720,548
1,260,147
833,069
36.5
51.3%
398,850
294,158
226,834
23.2%
23.3%
27.2%
S.G.A.
307,328
244,706
184,538
S.G.A
17.9%
19.4%
22.2%
Gross Margin
Operating Profit
$ 4.159,0 $ 3.753,0 $ 2.960,0
Operating Profit
105,220
69,770
47,701
EBITDA
$ 4.159,0 $ 3.753,0 $ 2.960,0
EBITDA
118,574
69,378
51,266
6.9%
5.5%
6.2%
EBITDA margin
7,5%
7,7%
6,6%
EBITDA margin
Source: Company reports;Annual Reports.
Source: Company reports;Annual Reports.
(All values US$000)
Comparative net sales
revenue
(All values R$000)
Comparative net sales revenue
(1/3)
28
DROGASIL: BENCHMARK
Aug-09
Aug-08
Aug-07
DROGASIL
Net Sales
Dec-09
Dec-08
Dec-07
1,720,548
1,260,147
833,069
36.5%
51.3%
398,850
294,158
226,834
23.2%
23.3%
27.2%
WALGREENS
Net Sales
$ 63,335.0
$ 59,034.0
$ 53,762.0
Sales Grwoth
7.3%
9.8%
13.4%
$ 17,613.0
$ 16,643.0
$ 15,244.0
27.8%
28.2%
28.4%
S.G.A.
$ 14,366.0
$ 13,202.0
$ 12,093.0
S.G.A.
307,328
244,706
184,538
S.G.A
22.7%
22.4%
22.5%
S.G.A
17.9%
19.4%
22.2%
Operating Profit
$ 3,164.0
$ 3,430.0
$ 3,189.0 Operating Profitl
105,220
69,770
47,701
EBITDA
$ 4,222.0
$ 4,281.0
$ 3,827.0
118,574
69,378
51,266
6.7%
7.3%
7.1%
6.9%
5.5%
6.2%
Gross Profit
Gross Margin
EBITDA margin
Sales Growth
Gross Profit
Gross Margin
EBITDA
EBITDA margin
Source: Company reports;Annual Reports.
Source: Company reports;Annual Reports.
(All values US$000)
Comparative Net Sales
(All values R$000)
Comparative Net Sales
(2/3)
29
680
630
580
530
480
Gap 23.6%
430
380
330
391
428
359
411
402
464
395
474
411
496
393
488
414
513
402
469
402
474
402
480
384
459
431
519
393
470
368
458
419
539
409
536
425
563
418
554
441
576
434
580
413
556
426
579
403
559
450
618
402
548
380
523
438
598
418
573
450
601
436
569
457
582
469
605
452
559
R$ Mil
DROGASIL: BENCHMARK
Drogasil X Abrafarma(-)Drogasil - BRASIL
Monthly Sales per Store
280
230
180
Abrafarma - Br
(3/3)
Drogasil - Br
30
DROGASIL: SHAREHOLDER RETURN
350
300
DROG3 , since IPO til Dec 2010.
Ibovespa Base 100= Jun 2007
250
200
150
100
50
0
DROG3
IBOVESPA
(1/6)
31
DROGASIL: SHAREHOLDER RETURN
350.000
16.000
300.000
14.000
12.000
250.000
10.000
200.000
303.463
156.275
163.586
75.432
66.411
92.646
54.743
81.471
72.732
45.893
76.868
100.000
6.000
146.661
150.000
50.000
8.000
4.000
2.000
000
000
Jan
Fev
Mar
Abr
Mai
Jun
DROG3 Volume (R$000)
(2/6)
Jul
Ago
Set
Out
Nov
Dez
DROG3- ADTV(R$000)
Source:
BM&FBovespa 2010
32
DROGASIL: SHAREHOLDER RETURN
Dividends & IOC
27.000,0
24.000,0
35%
27%
28%
18.000,0
26% 26%
15.000,0
17%
14.872
12.000,0
6.200
10.005
5.931
3.366
2.848
2.354
2.824
21.000,0
17.400
31%
19.422
29%
33%
5.350
34%
36%
24.390
35%
38%
9.000,0
6.000,0
3.000,0
0,0
Título do Eixo
IOC & Dividends
( R$000)
(3/6)
% NET PROFIT
33
DROGASIL: SHAREHOLDER RETURN
Recent Events:
Capital Stock
188.320.020
Shares
Capital Stock
R$ 285.400
Millions
Free Float
77.880.534
Shares
% Free Float
Share Price Jan 12, 2011
a) Split 1:3 ON.
b) IOC payment reference 1Q10 +2Q10 in 2010.
c) DROG3 is listed on ICON; IGCT BM&
41,36%
Bovespa indices – as of Jan 04, 2011.
R$ 13,94
IOC & Dividends
FY 2008
R$ 19.422
Millions
IOC & Dividends
FY 2009
R$ 24.390
Millions
IOC & Dividends
FY 2010
R$ 17.400
Millions
d) Shareholder return: 46,68%
(FY 2010 – source: Economática)
MARKET CAP DROG3
1.800.000
1.600.000
USD(30/09/2010)
R$ 1,69
1.400.000
E.V.
E.V. USD
$1.549.510,73
Millions
(R$ 60.255)
Millions
R$ 2.564.926
Millions
$1.513.945
Millions
1.200.000
R$ 1.660.988
NET DEBT (Sept 10)
Millions
R$ 590.600
MARKET CAP USD
R$ 2.625.181
R$ 900.793
MARKET CAP.
1.000.000
800.000
600.000
400.000
200.000
0
2007
4/6
2008
2009
34
DROGASIL: SHAREHOLDER RETURN
Corporate Governance
Board
CEO & Investment
Relations Director.
Fiscal
Board
Claudio Roberto Ely
C.F.O.
SALES
Director
Ricardo
Castro
Azevedo
Antonio
Carlos
Freitas
5/6
PURCHASE
Director
Carlos
Alberto
Dutra
35
DROGASIL:SHAREHOLDER RETURN
Corporate Governance
Free Float
30%
Carlos Pires Oliveira
Dias
26%
Fidelity Investments
12%
Members of the Board
7%
Buy Back
0%
Tantra
Participações
Ltda
10%
1% Executive Directors
Capital Research &
Mgmt
Regimar Comercial S.A
5%
9%
6/6
36
2010: A year of accomplishments...
37
Thank You
Drogasil S.A.
Avenida Corifeu de Azevedo Marques, nº 3.097
Vila Butantã – São Paulo
05339-900
Roberto Listik
Investment Relations Officer
Phone (+5511)3769-5670
[email protected]
Claudio Roberto Ely.
CEO & Investment Relations Director
[email protected]
38